Cancer Biological Therapy

Cancer Biological Therapy Market Outlook

The global cancer biological therapy market is projected to reach approximately USD 130 billion by 2035, growing at a CAGR of around 8.5% during the forecast period from 2025 to 2035. The increasing incidence of cancer worldwide, along with the growing awareness and acceptance of biologic therapies, is contributing significantly to the market's expansion. Advances in biotechnology and the growing number of clinical trials aimed at developing more effective and targeted treatments are also driving market growth. Furthermore, favorable government initiatives and funding for cancer research play a critical role in enhancing the development of novel biological therapies. By improving patient outcomes and survival rates, these therapies are becoming increasingly favorable in cancer treatment paradigms.

Growth Factor of the Market

One of the primary growth factors for the cancer biological therapy market is the rising prevalence of various types of cancer, which necessitates the development of innovative treatment modalities. With an increase in the aging population and lifestyle-related risk factors, the demand for effective cancer therapies is escalating. Moreover, ongoing research and technological advancements in biotechnology are enabling the discovery of new biological agents that enhance the efficacy of cancer treatment. The shift from traditional chemotherapy to more targeted biological therapies is also gaining traction due to the lower side effects associated with these treatments. Additionally, the increasing healthcare expenditure on cancer treatment and the establishment of specialized oncology centers worldwide are further driving the growth of this market.

Key Highlights of the Market

• The global cancer biological therapy market is anticipated to grow at a CAGR of 8.5% from 2025 to 2035.
• Monoclonal antibodies continue to dominate the product type segment due to their high specificity and efficacy.
• North America is expected to hold the largest market share, driven by advanced healthcare infrastructure and high investments in cancer research.
• Oncolytic virus therapy is emerging as a promising treatment option, gaining traction in clinical applications.
• The increasing collaboration between biopharmaceutical companies and research organizations is fostering innovation in cancer therapies.

By Product Type

Monoclonal Antibodies:

Monoclonal antibodies (mAbs) represent a significant segment within the cancer biological therapy market, accounting for a substantial share due to their targeted action against specific antigens. These antibodies can be engineered to bind to cancer cells, marking them for destruction by the immune system while minimizing damage to healthy cells. The efficacy of mAbs in treating various malignancies such as lymphoma, breast cancer, and colorectal cancer has spurred their widespread adoption. The introduction of biosimilars is also expected to enhance market accessibility and affordability, further propelling growth in this segment. With continuous advancements in antibody engineering and the development of combination therapies, the monoclonal antibodies segment is set to experience robust growth in the coming years.

Cancer Vaccines:

Cancer vaccines are another critical component of the biological therapy landscape, designed to stimulate the immune system to recognize and attack cancer cells. Unlike traditional vaccines that prevent infections, cancer vaccines aim to treat existing cancers or prevent cancer recurrence. The successful launch of therapeutic vaccines, such as Sipuleucel-T for prostate cancer, has paved the way for further research and development in this area. The market is expected to witness an increase in clinical trials evaluating various vaccine candidates, including personalized and neoantigen-based vaccines, which offer the potential for improved treatment outcomes. The growing recognition of the role of the immune system in cancer therapy is also propelling the development of innovative vaccine approaches in oncology.

Cytokines:

Cytokines play an essential role in cell signaling and the modulation of immune responses, making them a vital category in cancer biological therapy. They serve as mediators between immune cells and can enhance the body’s ability to fight cancer. Interferons and interleukins are the primary cytokines used in oncology, demonstrating efficacy in treating various cancers, including melanoma and renal cell carcinoma. The increasing understanding of cytokine biology has led to the exploration of novel combinations with other treatment modalities, such as immunotherapy, to improve patient outcomes. The market for cytokine-based therapies is anticipated to grow as more clinical evidence emerges regarding their effectiveness and safety profiles in cancer treatment.

Gene Therapy:

Gene therapy has emerged as a revolutionary approach in the treatment of cancer, focusing on correcting or replacing defective genes responsible for tumor growth. This innovative treatment modality holds the potential for long-lasting effects by targeting the genetic features of cancer cells. Gene editing technologies, such as CRISPR-Cas9, have enhanced the feasibility of developing targeted gene therapies, leading to significant advancements in personalized medicine. The successful application of gene therapy in clinical trials has generated substantial interest from pharmaceutical companies and investors alike, anticipating growth in this segment. As regulatory frameworks evolve to accommodate these new therapies, gene therapy is expected to increasingly influence the cancer biological therapy market.

Oncolytic Virus Therapy:

Oncolytic virus therapy, a unique and promising approach to cancer treatment, utilizes genetically modified viruses that selectively infect and destroy cancer cells while sparing normal cells. This therapeutic strategy capitalizes on the innate ability of certain viruses to replicate within and kill tumor cells, inducing an immune response against the cancer. The FDA’s approval of talimogene laherparepvec (T-VEC) has validated the clinical potential of oncolytic viruses in melanoma treatment. Ongoing research and clinical trials are focused on optimizing virus design and combining this therapy with other modalities, such as checkpoint inhibitors, to enhance efficacy. As understanding of viral interactions with the immune system deepens, this segment is poised for significant growth in the coming years.

By Application

Breast Cancer:

Breast cancer remains one of the most prevalent and challenging malignancies globally, leading to a high demand for effective biological therapies tailored for its treatment. Advances in targeted therapies, particularly monoclonal antibodies such as trastuzumab, have significantly improved patient outcomes and survival rates among HER2-positive breast cancer patients. Additionally, ongoing research into combination therapies integrating biological agents with traditional treatments is enhancing the effectiveness of breast cancer management. The growing focus on personalized medicine in oncology is further driving the development of biological therapies specifically targeting molecular subtypes of breast cancer, thus expanding treatment options for patients.

Lung Cancer:

Lung cancer is characterized by high morbidity and mortality rates, necessitating the development of innovative and effective treatment strategies. Biological therapies, notably targeted agents and immune checkpoint inhibitors, have transformed the treatment landscape for specific subtypes, particularly non-small cell lung cancer (NSCLC). The introduction of drugs such as pembrolizumab and nivolumab has provided patients with new options, demonstrating significant improvements in progression-free survival. Furthermore, the increasing prevalence of biomarker testing is enabling oncologists to tailor treatments based on individual patient profiles, fostering a more personalized approach to lung cancer therapy. As research continues into novel agents and combinations, the market for lung cancer biological therapies is set to grow substantially.

Prostate Cancer:

Prostate cancer therapies are witnessing a shift towards biological approaches, with significant advances in understanding the disease's molecular underpinnings. Hormonal therapies and immunotherapeutic agents are becoming standard care options for advanced prostate cancer. The successful use of sipuleucel-T has paved the way for the development of additional immune-based therapies. Furthermore, ongoing clinical trials exploring combination treatments, including hormone therapy and checkpoint inhibitors, are expected to yield promising results, enhancing overall survival rates among patients with prostate cancer. The growing awareness and acceptance of biological therapies in treating this disease are supporting market growth in this segment.

Colorectal Cancer:

Colorectal cancer is one of the leading causes of cancer mortality globally, prompting ongoing research and development of effective biological therapies. Targeted therapies, including monoclonal antibodies such as cetuximab and panitumumab, have become essential components of treatment regimens for metastatic colorectal cancer. The increased focus on personalized medicine and genomic profiling is facilitating the identification of specific mutations that inform treatment choices, improving patient outcomes. As more clinical data emerges, the integration of biological therapies with traditional treatments, such as chemotherapy, is expected to enhance therapeutic efficacy and drive market growth in this segment.

Blood Cancer:

Blood cancers, including leukemia and lymphoma, represent a crucial area of focus for cancer biological therapy development. The introduction of targeted agents and monoclonal antibodies has revolutionized treatment paradigms, providing new hope for patients with hematological malignancies. Therapies such as CAR T-cell therapy have shown remarkable success in treating certain types of blood cancer, illustrating the potential of innovative biological approaches. Moreover, the continuous exploration of combination therapies and investigational agents is expected to propel growth in this segment. The increasing prevalence of blood cancers and the successful outcomes associated with biological therapies are key drivers of this market's expansion.

By Distribution Channel

Hospitals:

Hospitals serve as a major distribution channel for cancer biological therapies, providing specialized care and a comprehensive range of treatment options for cancer patients. The presence of multidisciplinary oncology teams in hospitals facilitates the administration of complex biological therapies that require close monitoring and management. The growing number of cancer treatment centers and oncology departments within hospitals is further enhancing the accessibility of these therapies. As hospitals continue to adopt advanced technologies and improve their infrastructure, the demand for biological therapies is expected to rise, contributing to growth in this distribution channel.

Clinics:

Oncology clinics play a significant role in the distribution of cancer biological therapies, offering outpatient services that allow patients to receive treatment in a less intensive setting compared to hospitals. The convenience and flexibility of clinic-based therapies attract patients seeking to manage their cancer treatment while maintaining a higher quality of life. Additionally, clinics often emphasize personalized care, allowing oncologists to closely tailor treatment plans based on individual patient needs. As the trend toward outpatient care continues to grow, along with advancements in treatment protocols, the oncology clinic distribution channel is poised for significant growth in the cancer biological therapy market.

Retail Pharmacies:

Retail pharmacies are increasingly becoming an essential distribution channel for cancer biological therapies, particularly for oral medications and less complex therapies. The availability of these therapies at retail pharmacies enhances patient access and convenience, enabling individuals to obtain their medications without the need for hospital visits. Furthermore, the integration of specialty pharmacy services within retail chains allows for better management of medication therapy and patient support. As the landscape of cancer treatment continues to evolve, the role of retail pharmacies in dispensing biological therapies is expected to expand, driven by the demand for accessible patient care.

Online Pharmacies:

Online pharmacies have gained popularity as a distribution channel for cancer biological therapies, particularly in the wake of the growing trend toward telemedicine and remote healthcare solutions. The convenience of ordering medications online has become increasingly attractive to patients undergoing cancer treatment, allowing them to receive therapies without the challenges of traditional pharmacy visits. Additionally, online pharmacies often provide a wide range of products and patient support services, contributing to an improved patient experience. As regulatory frameworks evolve to accommodate online distribution of specialized therapies, this segment is likely to witness substantial growth in the coming years.

By Ingredient Type

Checkpoint Inhibitors:

Checkpoint inhibitors have emerged as a groundbreaking class of cancer therapies that enhance the immune system's ability to recognize and eliminate cancer cells. These agents work by inhibiting specific proteins that suppress immune responses, thus allowing T cells to mount a more robust attack against tumors. The success of checkpoint inhibitors such as pembrolizumab and nivolumab has transformed the treatment landscape for various cancers, including melanoma and lung cancer. As new checkpoint molecules are identified and novel combinations are explored, the market for checkpoint inhibitors is expected to continue growing significantly, driven by ongoing clinical trials and increasing adoption in clinical practice.

Growth Factor Inhibitors:

Growth factor inhibitors play a crucial role in cancer treatment by disrupting the signaling pathways that promote tumor growth and survival. These agents target specific growth factors and their receptors, effectively hindering the proliferation of cancer cells. The introduction of drugs such as trastuzumab and bevacizumab has showcased the potential of growth factor inhibitors in treating various malignancies, particularly breast and colorectal cancers. As ongoing research uncovers new targets and potential combinations, the importance of growth factor inhibitors within the cancer biological therapy market is anticipated to increase, contributing to the overall growth of this segment.

Immune System Modulators:

Immune system modulators are essential components of cancer biological therapy, designed to enhance the body's immune response against tumors. These agents, including various cytokines and immune checkpoint inhibitors, can help stimulate or restore immune function in cancer patients. The effectiveness of immune modulators in combination with existing treatment modalities has led to their growing adoption in oncology. As researchers continue to investigate new approaches to optimize immune responses, the demand for immune system modulators is expected to rise, driving growth within this segment of the cancer biological therapy market.

Gene Therapies:

Gene therapies represent a transformative approach to cancer treatment, targeting the genetic alterations that contribute to tumor development and progression. By directly modifying the genes within cancer cells, these therapies can induce cell death, restore normal function, or enhance immune responses against tumors. The progress made in gene editing technologies, such as CRISPR-Cas9 and CAR T-cell therapies, has accelerated the development of innovative gene therapies for various malignancies. As research advances and clinical evidence mounts, the gene therapy segment is poised for substantial growth, given its potential to revolutionize cancer treatment.

Oncolytic Viruses:

Oncolytic viruses represent a novel category of cancer therapies that exploit the natural ability of certain viruses to selectively infect and destroy cancer cells. Through careful engineering, these viruses can be optimized to enhance their efficacy while minimizing harm to healthy tissue. Recent advancements in oncolytic virus therapy, such as talimogene laherparepvec (T-VEC), have demonstrated promising results in clinical settings. As ongoing research explores new viral candidates and combination therapies, the market for oncolytic viruses is expected to expand, driven by increased clinical interest and patient demand for innovative cancer treatments.

By Region

The North American cancer biological therapy market is projected to maintain dominance throughout the forecast period, attributed to advanced healthcare infrastructure and significant investments in cancer research and development. The presence of leading biotechnology firms and research institutions in the United States is fostering innovation and accelerating the introduction of novel therapies into the market. Furthermore, the high prevalence of cancer cases, coupled with favorable reimbursement policies and increasing patient awareness regarding biological therapies, contributes to the market's growth in this region. It is anticipated that the North America market will experience a CAGR of around 9% during the forecast period.

Europe is also witnessing substantial growth in the cancer biological therapy market, driven by an increasing emphasis on personalized medicine and the integration of innovative therapies into clinical practice. Countries such as Germany, France, and the United Kingdom are leading the way in research initiatives and clinical trials aimed at improving treatment outcomes for cancer patients. Additionally, collaborations between governmental agencies and biopharmaceutical companies are fostering advancements in cancer therapy development. As regulatory approvals for new biologics continue to rise, the European market is expected to contribute significantly to the overall growth of the global cancer biological therapy landscape.

Opportunities

The cancer biological therapy market is poised for significant opportunities, particularly in the realm of personalized medicine. As the understanding of the genetic and molecular basis of cancer improves, there is a growing potential for developing tailored therapies that target specific patient populations based on their unique tumor profiles. This shift toward precision oncology is expected to lead to improved treatment outcomes and reduced toxicity, fostering increased adoption of biological therapies. Additionally, advancements in biomarker discovery and diagnostic technologies are likely to facilitate the identification of patients who would benefit most from targeted therapies, further enhancing market potential.

Moreover, the rising trend of collaboration and partnerships between biopharmaceutical companies, academic institutions, and research organizations presents substantial growth opportunities in the cancer biological therapy market. These collaborations can expedite the development of innovative therapies and allow for the sharing of knowledge, resources, and expertise. Furthermore, the increasing focus on global health initiatives aimed at improving access to cancer treatments in underserved populations creates a market opportunity for affordable and effective biological therapies. As more stakeholders unite in the fight against cancer, the landscape of biological therapy is likely to evolve, opening new avenues for growth and innovation.

Threats

Despite the promising outlook for the cancer biological therapy market, several threats could impede growth. One significant challenge is the high cost associated with developing and manufacturing biological therapies, which can limit patient access and create disparities in treatment availability. The complex nature of these therapies often translates to lengthy development timelines and high research expenditures, which can deter smaller companies from entering the market. Additionally, stringent regulatory requirements and the need for extensive clinical trials can delay product approvals and limit innovation, posing a threat to sustained market growth. Furthermore, the potential for adverse effects related to biological therapies may result in increased scrutiny from regulatory bodies and healthcare professionals, further complicating the market landscape.

Another considerable threat to the cancer biological therapy market lies in the rapid advancement of alternative treatment modalities, including small molecule drugs and immunotherapies. As new strategies emerge and gain traction in clinical practice, there is a risk that biological therapies may face competition from these alternatives, particularly if they demonstrate superior efficacy or reduced side effects. Additionally, the ongoing evolution of cancer treatment paradigms and shifting patient preferences may lead to decreased reliance on biological therapies in some instances. Companies must remain vigilant and adaptive to these market dynamics to ensure continued success in a rapidly changing healthcare environment.

Competitor Outlook

• Roche Holding AG
• Bristol Myers Squibb Company
• Amgen Inc.
• Merck & Co., Inc.
• Novartis AG
• AbbVie Inc.
• Pfizer Inc.
• Gilead Sciences, Inc.
• Johnson & Johnson
• AstraZeneca PLC
• Sanofi S.A.
• Celgene Corporation (acquired by Bristol Myers Squibb)
• Regeneron Pharmaceuticals, Inc.
• Seattle Genetics, Inc.
• Takeda Pharmaceutical Company Limited

The competitive landscape of the cancer biological therapy market is characterized by the presence of several leading biopharmaceutical companies that are actively engaged in research and development to bring novel therapies to the market. These companies are not only focusing on the development of innovative biological agents but are also investing heavily in strategic collaborations and partnerships to enhance their research capabilities and expand their product portfolios. The competitive dynamics are further influenced by the rapid advancements in technology and the increasing emphasis on personalized medicine, prompting companies to differentiate their offerings by targeting specific patient populations and unmet medical needs.

Roche Holding AG is a prominent player in the cancer biological therapy market, renowned for its extensive portfolio of targeted therapies and immuno-oncology products. The company's Herceptin and Avastin have established strong footholds in breast and colorectal cancer treatment, respectively. Roche's commitment to research and innovation, coupled with its robust pipeline of investigational therapies, positions it as a leader in the oncology landscape. Additionally, the company's strategic acquisitions and partnerships have further bolstered its capabilities in developing new biologics, ensuring its continued relevance in the evolving market.

Bristol Myers Squibb Company is another key competitor, recognized for its groundbreaking work in immuno-oncology with products like Opdivo and Yervoy, which have transformed treatment options for various cancer types. The company's aggressive research pipeline and focus on combination therapies highlight its commitment to addressing the challenges of treatment resistance in cancer. Furthermore, Bristol Myers Squibb’s acquisition of Celgene Corporation has expanded its capabilities in hematology and strengthened its position in the cancer biological therapy market. As the company continues to innovate and adapt to market trends, it is well-positioned to capitalize on the growing demand for effective cancer therapies.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca PLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Seattle Genetics, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Celgene Corporation (acquired by Bristol Myers Squibb)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cancer Biological Therapy Market, By Application
    • 6.1.1 Breast Cancer
    • 6.1.2 Lung Cancer
    • 6.1.3 Prostate Cancer
    • 6.1.4 Colorectal Cancer
    • 6.1.5 Blood Cancer
  • 6.2 Cancer Biological Therapy Market, By Product Type
    • 6.2.1 Monoclonal Antibodies
    • 6.2.2 Cancer Vaccines
    • 6.2.3 Cytokines
    • 6.2.4 Gene Therapy
    • 6.2.5 Oncolytic Virus Therapy
  • 6.3 Cancer Biological Therapy Market, By Ingredient Type
    • 6.3.1 Checkpoint Inhibitors
    • 6.3.2 Growth Factor Inhibitors
    • 6.3.3 Immune System Modulators
    • 6.3.4 Gene Therapies
    • 6.3.5 Oncolytic Virus
  • 6.4 Cancer Biological Therapy Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Cancer Biological Therapy Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cancer Biological Therapy market is categorized based on

By Product Type

• Monoclonal Antibodies
• Cancer Vaccines
• Cytokines
• Gene Therapy
• Oncolytic Virus Therapy

By Application

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Blood Cancer

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Checkpoint Inhibitors
• Growth Factor Inhibitors
• Immune System Modulators
• Gene Therapies
• Oncolytic Virus

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Holding AG
• Bristol Myers Squibb Company
• Amgen Inc.
• Merck & Co., Inc.
• Novartis AG
• AbbVie Inc.
• Pfizer Inc.
• Gilead Sciences, Inc.
• Johnson & Johnson
• AstraZeneca PLC
• Sanofi S.A.
• Celgene Corporation (acquired by Bristol Myers Squibb)
• Regeneron Pharmaceuticals, Inc.
• Seattle Genetics, Inc.
• Takeda Pharmaceutical Company Limited